Companies: 10,795·Total market cap: $144.5T
Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

ALGSNASDAQHealthcare● Active
$4.96
+$0.05(+1.02%)
Market Cap$30693581
P/E Ratio—
52W High$13.689
52W Low$4.8
SEC Filings

Aligos Therapeutics, Inc. (ALGS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001799448 · ALGS · NASDAQ · as of Jun 9, 2026

Filing snapshot

334
Total Filings
SCHEDULE 13G
Latest Form
2026-05-15
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001799448 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-05
Fiscal Year End
Mar 5, 2026
Accession No.
0001193125-26-092614
Primary Document
algs-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001799448 · Accession 0001193125-26-092614

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2026-05-07Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
FORM 8-K
2026-05-07
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-29
View
ARSARS
ARS
2026-04-29
View
DEF 14AProxy Statement
DEF 14A
2026-04-29
View
8-KCurrent Report
8-K
2026-04-21
View
8-KCurrent Report
8-K
2026-04-14
View
S-8Employee Stock Plan Registration
S-8
2026-03-05
View
10-KAnnual Report
10-K
2026-03-05
View
8-KCurrent Report
FORM 8-K
2026-03-05
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-02-19
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-11
View
Showing 1–15 of 236 filingsForm 4 / 144 hidden· 334 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001799448  |  Exchange: NASDAQ · Healthcare

Aligos Therapeutics, Inc. (NASDAQ: ALGS) has submitted 334 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001799448, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aligos Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Aligos Therapeutics, Inc. 10-K was filed on 2026-03-05 for fiscal year ending 2026. Historical ALGS 10-K annual reports are available from 2020 through 2026.

Investors researching Aligos Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
XFOR SEC Filings →MRSN SEC Filings →OKUR SEC Filings →KZR SEC Filings →FGEN SEC Filings →INMB SEC Filings →BRNS SEC Filings →SKYE SEC Filings →
→ ALGS Financials→ ALGS Earnings→ ALGS Insider Trades

Frequently Asked Questions

ALGS SEC Filings · 8 questions

Aligos Therapeutics, Inc. (ALGS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 334 filings and access original documents at no cost. Aligos Therapeutics, Inc.'s CIK is 0001799448.

ALGS SEC filingsAligos Therapeutics, Inc. SEC documentsfind ALGS 10-K